AstraZeneca, GlaxoSmithKline, Merck: Emerging Markets Earnings Roundup (Part 2 of 3)
This article was originally published in PharmAsia News
Executive Summary
A push in emerging markets continued in the second quarter with Big Pharma reporting flat U.S. sales and a challenging payer environment in Europe, with many reallocating resources from Europe and the U.S. to Asia and other emerging markets and seeking partnerships in those geographies. Analysts boosted earnings per share numbers to companies that disclosed detailed emerging markets sales data, such as AstraZeneca, which started the trend in Q1. As a recurring feature, PharmAsia News combs through quarterly earnings reports to bring together the earning season's Asia highlights.
You may also be interested in...
Pfizer, Roche, AstraZeneca: Emerging Markets Earnings Roundup (Part 3)
Year-end and Q4 pharma earnings results emphasized emerging markets as one positive in a challenging environment posed by U.S. healthcare reform and European price cuts and austerity measures. Pharma companies stressed cost-cutting actions such as restructuring their businesses and closing facilities in the U.S. and Europe, while simultaneously discussing increased resource allocation for Asia and other emerging markets.
Pfizer, Roche, AstraZeneca: Emerging Markets Earnings Roundup (Part 3)
Year-end and Q4 pharma earnings results emphasized emerging markets as one positive in a challenging environment posed by U.S. healthcare reform and European price cuts and austerity measures. Pharma companies stressed cost-cutting actions such as restructuring their businesses and closing facilities in the U.S. and Europe, while simultaneously discussing increased resource allocation for Asia and other emerging markets.
Emerging Markets Round Up From JP Morgan Healthcare Conference (Part 2 of 2)
[Editor's note: This is part two of a story carrying highlights on emerging markets from the annual JP Morgan Healthcare Conference in San Francisco last week.